Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

HealthLynked (HLYK) EBIT (2016 - 2025)

HealthLynked (HLYK) has disclosed EBIT for 10 consecutive years, with -$736654.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 55.92% to -$736654.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.1 million, a 38.51% increase, with the full-year FY2024 number at -$4.7 million, down 12.67% from a year prior.
  • EBIT was -$736654.0 for Q3 2025 at HealthLynked, down from -$682780.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.3 million in Q4 2021 to a low of -$4.1 million in Q4 2022.
  • A 5-year average of -$1.2 million and a median of -$1.1 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 422.58% in 2022, then skyrocketed 73.2% in 2023.
  • HealthLynked's EBIT stood at $1.3 million in 2021, then plummeted by 422.58% to -$4.1 million in 2022, then surged by 73.2% to -$1.1 million in 2023, then surged by 32.67% to -$748774.0 in 2024, then rose by 1.62% to -$736654.0 in 2025.
  • Per Business Quant, the three most recent readings for HLYK's EBIT are -$736654.0 (Q3 2025), -$682780.0 (Q2 2025), and -$931365.0 (Q1 2025).